Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium

SAN DIEGO--(BUSINESS WIRE)-- Actio Biosciences, a clinical-stage biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 16th in Boston.

About Actio Biosciences

Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit ActioBiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409407683/en/

Katie Engleman, 1AB
[email protected]

Source: Actio Biosciences

You May Also Be Interested In

• Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease
• Vertical Aerospace Strengthens Supplier Network With ANH Structure and Northrop Grumman LITEF
• Westwater Resources Reports Strong Progress in Advancing the Coosa Graphite Mine